Follow us on Twitter
twitter icon@FreshPatents


Cytokine patents

      

This page is updated frequently with new Cytokine-related patent applications.




 Culture medium for hematopoeitic stem cells and the applications thereof as well as the stem cells culture method patent thumbnailnew patent Culture medium for hematopoeitic stem cells and the applications thereof as well as the stem cells culture method
The present invention discloses a culture medium for hematopoietic stem cells and the applications thereof as well as the stem cells culture method, which adopts amino acids, vitamins, salts, lipids, protein polypeptides and cytokines, together with one or several of trace elements, small organic molecules, hematopoietic stem cell proliferation agents, plant extracts and animal tissue cell extracts, to compose the hematopoietic stem cell culture medium, which can quickly proliferate different species of cd34+ cells, and improve both the proliferation speed and telomere length of cd34+ cells significantly; also, hematopoietic stem cells cultured in the hematopoietic stem cell culture medium described in the present invention may keep their cell functions as well, achieve the functions include but not limited to anti-tumor, anti-aging, and extending lives, thus having a pretty good application prospect.. .
China Life Science Technology Group Limited


 Cytokine receptor peptides, compositions thereof and methods thereof patent thumbnailnew patent Cytokine receptor peptides, compositions thereof and methods thereof
The invention provides a pharmaceutical composition including a peptide comprising at least a portion of a chemokine receptor or a g-protein coupled receptor and optionally a cytokine. The pharmaceutical composition of the invention may be used for altering immune system functioning, for example, to treat an immune system disorder, such as an autoimmune disease, multiple sclerosis, transplant rejection, psoriasis and asthma.
Symthera Canada Ltd.


 Methods for testing t cell priming efficacy in a subject patent thumbnailMethods for testing t cell priming efficacy in a subject
The present invention relates to methods for testing t cell priming efficacy in a subject. In particular the present invention relates to an in vitro method for testing t cell priming efficacy in a subject comprising the steps of a) providing sample from the subject, b) culturing the sample in a medium which induces the differentiation of dendritic cells, c) maturing the dendritic cells obtained at step a) in presence of an amount of at least one antigen and an amount of at least one cytokine or ligand suitable for the activation of a pathogen recognition receptor, d) priming and expanding the t cells present in the sample and e) analyzing the func tionality of the primed t cells..
UniversitÉ Paris - Sud


 Blood derived immune stimulatory compositions patent thumbnailBlood derived immune stimulatory compositions
Neutrophil extracellular traps (nets) are webs of dna held together with immunogenic peptides, released by neutrophils subsequent to activation. Nets are the most potent stimulator of dendritic cells, monocytes and t cells given their ability to activate tlr3, tlr4, tlr7 and tlr9.
Batu Biologics, Inc.


 Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy patent thumbnailMultimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
The present invention concerns multimeric complexes based on antibody fusion proteins comprising an ad moiety attached to the c-terminal end of each antibody light chain. The complexes further comprise effector moities attached to ddd moieties.
Ibc Pharmaceuticals, Inc.


 Compositions and methods for targeted immunomodulatory antibodies and fusion proteins patent thumbnailCompositions and methods for targeted immunomodulatory antibodies and fusion proteins
The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance.
The Johns Hopkins University


 Immunomodulatory agents patent thumbnailImmunomodulatory agents
The invention provides antibodies that specifically bind to pd-l1 and fusion molecules comprising pd-l1 binding proteins constructed with an il15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit pd-l1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases..
Kadmon Corporation, Llc


 Antigen-specific immunotherapy using tolerizing liposomes patent thumbnailAntigen-specific immunotherapy using tolerizing liposomes
The invention relates to a pharmaceutical composition for the treatment of allergic and autoimmune diseases by in vivo generation of tolerogenic dendritic cells (dcs) and macrophages using tolerizing liposomes loaded with at least one maturation inhibitor of dcs and at least one antigen or allergen or peptide derived thereof, made of at least one preparation, and comprising a matrix suitable for locally restricted sustained release of therapeutically effective doses of therapeutics including tolerogenic liposomes tailored for effective phagocytosis, at least one immune modulator of phagocytosis, and optionally at least one immune modulator suitable for enhancing the suppressive function of regulatory t cells and/or inhibiting the production of pro-inflammatory cytokines, and/or inhibiting the biological activity of secreted pro-inflammatory cytokines at the site of antigen or allergen presentation.. .
Pls-design Gmbh


 Methods for removing cytokines from blood with surface immobilized polysaccharides patent thumbnailMethods for removing cytokines from blood with surface immobilized polysaccharides
The present invention is directed to a method for removing cytokines and/or pathogens from blood or blood serum (blood) by contacting the blood with a solid, essentially non micro-porous substrate which has been surface treated with heparin, heparan sulfate and/or other molecules or chemical groups (the adsorbent media or media) having a binding affinity for the cytokine or pathogen(s) to be removed (the adsorbates), and wherein the size of the interstitial channels within said media is balanced with the amount of media surface area and the surface concentration of binding sites on the media in order to provide adequate adsorptive capacity while also allowing relatively high flow rates of blood through the adsorbent media.. .
Exthera Medical Corporation


 Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) patent thumbnailMethods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis..
Five Prime Therapeutics, Inc.


Inhibition of il-17 production

The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (il-17) by t cells, using an antagonist of interleukin-23 (il-23). The invention further concerns the use of il-23 antagonists in the treatment of inflammatory diseases characterized by the presence of elevated levels of il-17.
Genentech, Inc.

Methods and compositions relating to p62/sqstm1 for the treatment and prevention of inflammation-associated diseases

Provided herein are novel p62 compositions for the modulation of expression of a proinflammatory cytokines, osteogenic transcription factors, a bone resorptive factors and endogenous p62. Consequently, such p62 compositions are useful for prophylaxis and treatment of inflammatory diseases and related methods.
Curelab Oncology, Inc.

Il-15 and il-15r\alpha sushi domain based immunocytokines

The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and a polypeptide comprising the amino acid sequence of the sushi domain of the il-15rα or derivatives thereof; and uses thereof.. .
Inserm

T cell modulator

Compositions, methods of use, and pharmaceutical preparations useful for modulation of immune responses are disclosed herein. In one embodiment a composition is extracted from immune organs or leukocytes derived from members of the chondrichthyes family through dialysis.

Monoclonal antibodies that bind both il-17a and il-17f

The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of il-17a and il-17f. Il-17a and il-17f are cytokines that are involved in inflammatory processes and human disease.
Zymogenetics, Inc.

Activators of myosin ii for modulating cell mechanics

The present invention discloses small molecule compounds as activators of myosin ii by promoting its assembly and recruitment to contractile structures in the cell and methods of using such compounds. These compounds are useful to modulate cell and tissue mechanics.
The Johns Hopkins University

Transdiscal administration of specific inhibitors of pro-inflammatory cytokines

The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.. .
Depuy Synthes Products, Llc

Uses of kappa opioid synthetic peptide amides

The invention relates to methods of use of synthetic peptide amides that are ligands of the kappa opioid receptor in the treatment and prevention of kappa opioid receptor-associated diseases and conditions; and particularly to uses of these agonists in the prophylaxis, inhibition and treatment of pain, inflammation and pruritis associated with a variety of diseases, disorders and conditions. Inflammatory conditions preventable or treatable by the methods of the invention include diseases and conditions associated with elevated levels of a proinflammatory cytokines, such as tnf-α, il-1β, il-6, mmp-1 and mmp-3.
Cara Therapeutics, Inc.

Transdiscal administration of specific inhibitors of pro-inflammatory cytokines

The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.. .
Depuy Synthes Products, Llc

Transdiscal administration of specific inhibitors of pro-inflammatory cytokines

The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.. .
Depuy Synthes Products, Llc

Transdiscal administration of specific inhibitors of pro-inflammatory cytokines

The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.. .
Depuy Synthes Products, Llc

Transdiscal administration of specific inhibitors of pro-inflammatory cytokines

The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.. .
Depuy Synthes Products, Llc

Transdiscal administration of specific inhibitors of pro-inflammatory cytokines

The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.. .
Depuy Synthes Products, Llc

Small molecule enhancer for dendritic cell cancer vaccines

Disclosed is a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian dash serine proteases. Also disclosed is a method of (a) increasing antitumor immunity, (b) stimulating or enhancing an immune response, (c) treating a condition characterized by abnormal cell proliferation, (d) increasing cytokine and/or chemokine production, or (e) stimulating or enhancing production of t-cells, in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian dash serine proteases.
Trustees Of Tufts College

Methods of developing selective peptide antagonists

Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families.
Bioniz, Llc

Measuring embryo development and implantation potential with timing and first cytokinesis phenotype parameters

Methods, compositions and kits for determining the developmental potential of one or more embryos are provided. These methods, compositions and kits find use in identifying embryos in vitro that are most useful in treating infertility in humans..
Progyny, Inc.

Inhibitors of immune checkpoint modulators and related methods

The present disclosure relates to the use mnk-specific inhibitors to inhibit immunosuppression components, such as immune checkpoint proteins pd-1, pd-l1, lag3, and/or immunosuppressive cytokines, such as il-10, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease.. .
Effector Therapeutics, Inc.

Identification of a novel b cell cytokine

Compositions and methods involving il40, a novel cytokine produced by activated b cells, are provided. The compositions include: a) anti-il40 antibodies, il40 peptides and il40 proteins; b) nucleic acids encoding il40 gene and cdna sequences; and c) pharmaceutical compositions thereof.
The Regents Of The University Of California

Method of treating scoliosis using a biological implant to scoliosis

The present invention is a bone growth stimulating and promoting cytokine type biological implant preferably comprising pth coated with a controlled release biodegradable coating that is implanted preferably in the concave side of a scoliotically curved spine in combination with a bone growth inhibiting type biological implant preferably comprising methotrexate or like anti-metabolite coated with a controlled release biodegradable coating that is implanted preferably in the convex side of a scoliotically curved spine. The insertion of the biological implant is highly non-invasion, especially as compared to more conventional spine surgical methods, and the biological implant does not decrease spinal mobility or spinal range of motion..

Alkoxy substituted imidazoquinolines

Imidazoquinoline compounds with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.. .
3m Innovative Properties Company



Cytokine topics:
  • Antibodies
  • Inflammation
  • Specificity
  • Immunotherapy
  • Major Histocompatibility Complex
  • Compatibility
  • Combination Therapy
  • Histocompatibility
  • Immune Response
  • Monoclonal Antibody
  • Stimulator
  • Therapeutics
  • Immunostimulator
  • Monoclonal
  • Proinflammatory


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Cytokine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cytokine with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.69

    file did exist - 2266

    1 - 1 - 51